Core Viewpoint - The article discusses a significant breakthrough in diabetes cell therapy, focusing on the challenge of maintaining the long-term survival and functionality of transplanted pancreatic β cells in the diabetic microenvironment, which has been a major barrier to clinical application and large-scale promotion of such therapies [2][8]. Group 1: Research Findings - The study published by the team from Tongji University reveals that zinc accumulation during diabetes progression leads to the loss of β cell identity, which is a critical mechanism in the pathogenesis of diabetes [3][5]. - The research identifies the transporter protein ZnT8 as a crucial target for diabetes prevention and treatment, as it mediates the abnormal accumulation of zinc ions in β cells [5][6]. Group 2: Innovative Approaches - The research team proposes a novel technology pathway called "resilient pancreatic organoids," which focuses on enhancing the stability and survival of pancreatic organoids under metabolic stress, addressing the long-term efficacy issues in diabetes cell therapy [6][8]. - By targeting the specific zinc transporter ZnT8, the team effectively inhibits the pathological accumulation of zinc ions in β cells, thereby protecting their identity and improving their therapeutic efficacy in diabetic conditions [6][10]. Group 3: Clinical Implications - This study represents a structural adjustment in the paradigm of diabetes cell therapy, emphasizing the need for long-term maintenance of β cell stability rather than viewing them as merely consumable functional units [8]. - The advancements made by the research team are aimed at accelerating the clinical translation of resilient pancreatic organoid technology, which has the potential to redefine diabetes treatment and benefit millions of patients globally [10].